Analytical Data
-
Gene name
PDGF R beta
-
简介
PDGF R beta, a tyrosine-protein kinase receptor, crucially regulates embryonic development, overseeing cell processes like proliferation, survival, differentiation, chemotaxis, and migration. Especially vital in blood vessel development, it facilitates pericyte and smooth muscle cell proliferation, migration, and recruitment to endothelial cells, playing a significant role in blood vessel formation and maintenance. PDGF R beta Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived PDGF R beta protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
Biological Activity
Measured by its ability to inhibit the biological activity of PDGF-BB using NIH-3T3 mouse fibroblast cells. The ED50 for this effect is 2.236 µg/mL in the presence of 50 ng/mL Recombinant Human PDGF-BB, corresponding to a specific activity is 447.22 Unit/mg. Measured by its ability to inhibit the biological activity of PDGF-BB using NIH-3T3 mouse fibroblast cells. The ED50 for this effect is 2.236 µg/mL in the presence of 50 ng/mL Recombinant Human PDGF-BB, corresponding to a specific activity is 447.22 unit/mg.
-
Alternative Names
Platelet-derived growth factor receptor beta; PDGF-R-beta; PDGFR-1; CD140b; PDGFRB
-
Species
Rhesus Macaque
-
Source
HEK293
-
Tag
C-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
F7BTH1
-
Expression Region
L33-F530
-
AA Sequence
LVITPPGPELILNVSSTFVLTCSGSAPVVWERMSQELPQEMAKAQDNTFSSVLTLTNLTGLDTGEYFCTYNDSRGLEPDERKRLYIFVPDPTMGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDIALPVPYDHQRGFSGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGNEVVNFEWMYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDHQDEKAINITVVESGYVRLLGEVGALQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDSSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVLELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPMLLGNSSEEESQLETNVTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDMQEVIVVPHSLPF
-
Protein Length
Partial
-
Molecular Weight
80-96 kDa.
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Platelet-derived growth factor receptor beta (PDGFR-β) is a critical receptor involved in various cellular processes, including cell proliferation, survival, and migration, playing a significant role in development, wound healing, and tissue repair. Aberrant activation of PDGFR-β is implicated in a variety of pathological conditions such as cancer, fibrosis, and cardiovascular diseases. Consequently, understanding PDGFR-β signaling pathways and its interactions with ligands has become a focal point in biomedicine. Recombinant PDGFR-β proteins are utilized in research to elucidate the receptor's structure-function relationships and to develop therapeutic strategies targeting PDGFR-β in diseases. The production of these recombinant proteins, typically through techniques such as recombinant DNA technology and expression systems in bacteria or mammalian cells, allows for detailed studies of the receptor's biochemical properties and biological activities. Insights gained from such research can aid in the design of small-molecule inhibitors or monoclonal antibodies that specifically target PDGFR-β, offering potential treatments for conditions where its dysregulation is a contributing factor. Thus, the study of PDGFR-β recombinant proteins is vital in advancing our understanding of its role in health and disease, and holds promise for the development of innovative therapeutic approaches.
